Brief: Pfizer Says Drug Pricing Agreement With US Government Has No Impact On 2025 Guidance

Metsera

04/11/2025 14:50

Nov 4 (Reuters) - Pfizer:

PFIZER CEO SAYS "OUR BELIEF IN THE PROMISE OF THE PFIZER AND METSERA COMBINATION IS STRONG AND UNWAVERING" - PREPARED REMARKS

PFIZER:  PLANNING TO START PHASE 3 FOR ADULT 25-VALENT PROGRAM STUDY NEXT YEAR, IF FDA ALIGNS WITH OUR APPROACH - PREPARED REMARKS

PFIZER: FOR ABRYSVO, IN U.S., EXPERIENCING HEADWIND OF MORE DIFFICULT TO ACTIVATE POPULATION AS WE ENTER THIRD SEASON OF RSV - PREPARED REMARKS

PFIZER CFO: GOING FORWARD, COST MANAGEMENT ACROSS OUR MANUFACTURING NETWORK REMAINS A TOP PRIORITY - PREPARED REMARKS

PFIZER: DRUG PRICING AGREEMENT WITH US GOVERNMENT HAS NO IMPACT ON 2025 GUIDANCE, EXPECT DILUTIVE IMPACT TO 2026 FINANCIAL OUTLOOK - PREPARED REMARKS

PFIZER: THERE IS SOFTNESS IN OUR COVID PRODUCTS DUE TO LOWER VACCINATION RATES AND COVID INFECTION RATES - PREPARED REMARKS

PFIZER: NOW EXPECT 2025 ADJUSTED RESEARCH AND DEVELOPMENT TO BE IN THE RANGE OF $10.0 BILLION TO $11.0 BILLION - PREPARED REMARKS

Further company coverage: PFE.N

 ((Reuters.Briefs@thomsonreuters.com;))